Leaders Engaged on Alzheimer’s Disease (LEAD) is a diverse and growing national coalition of 59 member organizations including patient advocacy and voluntary health non-profits, philanthropies and foundations, trade and professional associations, academic research and clinical institutions, and biotechnology and pharmaceutical companies. LEAD is co-convened by the Alzheimer’s Foundation of America and USAgainstAlzheimer’s. The coalition works collaboratively to focus the nation’s strategic attention on Alzheimer’s disease and related disorders and to accelerate transformational progress in care and support, detection and diagnosis, and research leading to prevention, effective treatment and eventual cure.
LEAD May newsletter now available
LEAD Coalition Calls on Congress to Increase Research, Care and Support Appropriations
Sixty LEAD Coalition member organizations and supporters wrote to the U.S. House and Senate appropriations leadership in support of the Administration’s fiscal year 2014 budget proposal to provide an additional $80 million for Alzheimer’s disease and related disorders research at the National Institutes of Health and an additional $20 million Continuing reading…
LEAD Coalition Urges CMS to Approve PET Amyloid Imaging
Thirty-seven LEAD Coalition member organizations and supporters wrote to the Centers for Medicare and Medicaid Services (CMS) to encourage issuance of a National Coverage Decision with immediate effect for PET amyloid imaging in the evaluation of progressive cognitive decline when its use follows the appropriate use criteria (AUC) developed by Continuing reading…
LEAD April Newsletter Now Available
LEAD Coalition Comments on FDA Draft Guidance for Development of Drugs for Early Stage Alzheimer’s Disease
Forty-seven LEAD Coalition member organizations and supporters joined together to submit formal comment welcoming the U.S. Food and Drug Administration (FDA) draft guidance which outlines FDA’s current thinking as to how to a drug developer may demonstrate efficacy in clinical trials in patients in the early stages of Alzheimer’s disease that occur before the onset of overt dementia. Read more…
LEAD March Newsletter Now Available
LEAD Responds to National Institute on Aging Request for Information About Improving Alzheimer’s Disease Clinical Trials
LEAD Coalition Executive Director Ian Kremer wrote to the National Institute on Aging to propose a range of specific actions and to call for genuine, candid, persistent, inclusive collaboration by all stakeholders. Read more…